Notice Information
Notice Title
NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin
Notice Description
National Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin. The framework will commence on 1 July 2021 for a period of 18 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for a list of the purchasing points.
Lot Information
Lot No: 1-9
NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin. The framework will commence on 1 July 2021 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
Lot 1 - 5% Intravenous Immunoglobulin (5% IVIg)This modification notice is to provide notice of the modification of the framework agreement (as defined below) to (i) extend its duration with a limited number of suppliers and (ii) increase the estimated value of the framework agreement across all lots.
The modification is further described in sections VII.2.1 and VII.2.2 below, but in short NHS England were required to (i) modify the Current Framework with the Absent Suppliers (as defined below) so as to extend the Current Framework for those Absent Products (as defined below) for a further period of (i) 3-months for IVIg products (Lots 1, 2, 5 and 6) (so to 30th September 2025) and (ii) 6-months for SCIg products (Lots 3 and 7) (so to 31st December 2025) and (ii) increase the estimated value of the Current Framework from PS1.2bn to PS1.6bn (an increase of 33%).
Options: option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
Lot 2: 10% Intravenous Immunoglobulin (10% IVIg)10% Intravenous Immunoglobulin (10% IVIg)
Options: option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
Lot 3: Subcutaneous Immunoglobulin (SCIg)Subcutaneous Immunoglobulin (SCIg)
Options: option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
Lot 4: Facilitated Subcutaneous Immunoglobulin (fSCIg)Facilitated Subcutaneous Immunoglobulin (fSCIg)
Options: option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
Lot 6: 10% Intravenous Immunoglobulin (10% IVIg)10% Intravenous Immunoglobulin (10% IVIg)
Options: option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
Lot 5: 5% Intravenous Immunoglobulin (5% IVIg)5: 5% Intravenous Immunoglobulin (5% IVIg)
Options: option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
Lot 7: Subcutaneous Immunoglobulin (SCIg)Subcutaneous Immunoglobulin (SCIg)
Options: option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
Lot 9: Anti-D Immunoglobulin (Anti-D)Anti-D Immunoglobulin (Anti-D)
Options: option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
Lot 8: Facilitated Subcutaneous Immunoglobulin (fSCIg)Facilitated Subcutaneous Immunoglobulin (fSCIg)
Options: option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
Notice Details
Publication & Lifecycle
- Open Contracting ID
- ocds-h6vhtk-028c7b
- Publication Source
- Find A Tender Service
- Latest Notice
- https://www.find-tender.service.gov.uk/Notice/040406-2024
- Current Stage
- Award
- All Stages
- Tender, Award
Procurement Classification
- Notice Type
- Tender Notice
- Procurement Type
- Framework
- Procurement Category
- Goods
- Procurement Method
- Open
- Procurement Method Details
- Open procedure
- Tender Suitability
- Not specified
- Awardee Scale
- Large, SME
Common Procurement Vocabulary (CPV)
- CPV Divisions
33 - Medical equipments, pharmaceuticals and personal care products
-
- CPV Codes
33651520 - Immunoglobulins
Notice Value(s)
- Tender Value
- £1,200,000,000 £1B-£10B
- Lots Value
- Not specified
- Awards Value
- Not specified
- Contracts Value
- £1,600,000,001 £1B-£10B
Notice Dates
- Publication Date
- 16 Dec 20241 years ago
- Submission Deadline
- 26 Feb 2021Expired
- Future Notice Date
- Not specified
- Award Date
- 22 Jun 20214 years ago
- Contract Period
- 30 Jun 2021 - 31 Mar 2025 3-4 years
- Recurrence
- Not specified
Notice Status
- Tender Status
- Complete
- Lots Status
- Active, Cancelled
- Awards Status
- Active
- Contracts Status
- Active
Buyer & Supplier
Contracting Authority (Buyer)
- Main Buyer
- NHS ENGLAND
- Additional Buyers
THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND)
- Contact Name
- Mark Perkins, Philip Grieve
- Contact Email
- mark.perkins@nhs.net, philip.grieve@nhs.net
- Contact Phone
- Not specified
Buyer Location
- Locality
- RUNCORN
- Postcode
- WA7 2ES
- Post Town
- Warrington
- Country
- England
-
- Major Region (ITL 1)
- TLI London
- Basic Region (ITL 2)
- TLI4 Inner London - East
- Small Region (ITL 3)
- TLI45 Lambeth
- Delivery Location
- Not specified
-
- Local Authority
- Lambeth
- Electoral Ward
- Waterloo & South Bank
- Westminster Constituency
- Vauxhall and Camberwell Green
Further Information
Open Contracting Data Standard (OCDS)
View full OCDS Record for this contracting process
The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.
{
"tag": [
"compiled"
],
"id": "ocds-h6vhtk-028c7b-2024-12-16T11:04:30Z",
"date": "2024-12-16T11:04:30Z",
"ocid": "ocds-h6vhtk-028c7b",
"description": "VII.2.1.1 Nature/Extent of Modifications<br/>This modification notice is to provide notice of a modification of the framework agreement (as defined below) to (i) extend its duration with a limited number of suppliers and (ii) increase the estimated value of the framework agreement across all lots. <br/>This framework agreement was awarded as per publication reference 2021/S 000-017380 in August 2021 (the \"Current Framework\"). The term of the Current Framework was for an initial period from 1st July 2021 to 31st December 2022 with optional extension periods of up to 30 months (i.e. to 30th June 2025). <br/><br/>Duration Modification<br/><br/>NHS England has previously exercised its right to extend the Current Framework to 31st March 2025 and recently undertook a new procurement for the award of new framework agreements to commence from 1st April 2025 (the \"New Framework\") for the supply of the same/similar products. The awarded value of the Current Framework was PS1.2bn. <br/>However, there are four suppliers - LFB Biomedicaments (Lots 2 and 6), CSL Behring Ltd (Lots 2, 3, 6 and 7), Bio Products Laboratory (Lot 2, 3, 6 and 7), and Grifols UK Ltd (Lots 1 and 5) - on the Current Framework who have either (i) not been awarded a place on the New Framework or (ii) have been awarded a place on the New Framework as a reserve supplier and therefore have no committed volumes or guarantee of supply (the \"Absent Suppliers\") in respect of the products that they currently supply under the Current Framework (the \"Absent Products\"). Some patients are reliant upon Absent Products and will require switching to products supplied by suppliers awarded guaranteed supplies on the New Framework (the \"New Products\"). Changing a patient from Absent Products to a New Product needs to be appropriately managed. The scale of changes required to patient treatment resulting from the new procurement are higher than expected and cannot be completed prior to the commencement of the New Framework. In order to safely switch patients, more time will be required than could have been foreseen. This switching process will be undertaken over a period of time as is clinically appropriate considering patients' needs and clinical resources. In order to ensure continuity of supply of medicines from current suppliers during the transition period, NHS England will extend the Current Framework for IVIg products by 6 months and for SCIg products by 9 months.<br/>In order to secure continued routine access to Absent Products for a period of time to allow the safe switching of products, NHS England were required to extend the duration of the Current Framework with those Absent Suppliers in respect of the Absent Products for a period of time. <br/>NHS England have exercised their contractual right to extend the Current Framework with the Absent Suppliers for a further 3-months to 30th June 2025 and therefore NHS England are not required to rely on regulation 72 of the Public Contracts Regulations 2015 to extend for that period of time. The value of supply of products during this extended period is estimated to be c.PS34,056,162.<br/>However, a further period of time beyond that contractually entitled period was also required. As such, NHS England were required to modify the Current Framework with the Absent Suppliers so as to extend the Current Framework for those Absent Products for a further period of (i) 3-months for IVIg products (Lots 1, 2, 5 and 6) (so to 30th September 2025) and (ii) 6-months for SCIg products (Lots 3 and 7) (so to 31st December 2025) (the \"Duration Modification\"). <br/>The awarded value of the Current Framework was PS1.2bn. The Duration Modification will increase the framework value by c.PS15,036,879 which is within the allowed 50% threshold.<br/><br/>Value Modification<br/><br/>Additionally, NHS England is required to increase the estimated value of the Current Framework. The estimated awarded value of the Current Framework was PS1.2bn. NHS England estimates that the total requirement for purchase of products across the lifetime of the Current Framework up to the expiry of the Current Framework on 31st March 2025 will now be an increased figure of PS1.6bn and are therefore increasing the estimated value from PS1.2bn to PS1.6bn (an increase of 33%) (the \"Value Modification\"). This increase in value is due to a combination of (i) an increase in demand for products and (ii) increase in pricing of the products as a result of inflation and increase in Voluntary Pricing and Access Scheme (\"VPAS\") rebate scheme. This also includes the value of the Duration Modification. <br/><br/>VII.2.2.2 Description of reason - <br/>Duration Modification<br/><br/>The requirement to extend for that additional period of time has become necessary and is permitted by Regulation 72(1)(b) and or (c) of The Public Contacts Regulations 2015. Namely, the following conditions have been fulfilled: (i) additional supplies of products by the original contractors (i.e. the Absent Suppliers) have become necessary so as to secure continuity of products to allow the transition of patients to products on the New Framework and were not included in the initial procurement (ii) a change of contractor cannot be made for technical reasons of interchangeability with existing supplies as those patients will require switching between products over a period of time under supervision of clinicians and/or would cause significant inconvenience (iii) the increase in price of the modification does not exceed 50% of the original contract value. <br/>Additionally or alternatively (i) the need for modification has been brought about by circumstances which a diligent contracting authority could not have foreseen (ii) the modification does not alter the overall nature of the contract as it continues to be a framework agreement for supply of the same/similar products and (iii) the increase in price of the modification does not exceed 50% of the original contract value. <br/><br/>Value Modification<br/><br/>The Value Modification has become necessary and is permitted by Regulation 72(1)(b), (c) and/or (e) of the Public Contacts Regulations 2015. Namely, the following conditions have been fulfilled: (i) additional supplies of products by the original contractors (i.e. all of those suppliers appointed on the Current Framework) have become necessary so as to secure continuity of products and were not included in the initial procurement (ii) a change of contractor cannot be made for technical reasons of interchangeability with existing supplies as patients require continuity of supply of the products on the Current Framework until the expiry of the Current Framework and commencement of the New Framework (where save for the Absent Suppliers the majority of the suppliers on the Current Framework are also appointed to the New Framework) (iii) the increase in price of the modification does not exceed 50% of the original contract value. <br/>Additionally or alternatively (i) the need for modification has been brought about by circumstances which a diligent contracting authority could not have foreseen (ii) the modification does not alter the overall nature of the contract as it continues to be a framework agreement for supply of the same/similar products and (iii) the increase in price of the modification does not exceed 50% of the original contract value. <br/>Finally, the Value Modification is not substantial (as set out in regulation 72(8)) and therefore is permissible pursuant to regulation 72(1)(e).",
"initiationType": "tender",
"tender": {
"id": "ocds-h6vhtk-028c7b",
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"title": "NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "complete",
"classification": {
"scheme": "CPV",
"id": "33651520",
"description": "Immunoglobulins"
},
"mainProcurementCategory": "goods",
"description": "National Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin. The framework will commence on 1 July 2021 for a period of 18 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for a list of the purchasing points.",
"value": {
"amount": 1200000000,
"currency": "GBP"
},
"lots": [
{
"id": "1-9",
"title": "Lot No: 1-9",
"description": "NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin. The framework will commence on 1 July 2021 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.",
"contractPeriod": {
"startDate": "2021-07-01T00:00:00+01:00",
"endDate": "2022-12-31T23:59:59Z"
},
"hasRenewal": false,
"submissionTerms": {
"variantPolicy": "notAllowed"
},
"hasOptions": false,
"status": "active"
},
{
"id": "1",
"title": "Lot 1 - 5% Intravenous Immunoglobulin (5% IVIg)",
"description": "This modification notice is to provide notice of the modification of the framework agreement (as defined below) to (i) extend its duration with a limited number of suppliers and (ii) increase the estimated value of the framework agreement across all lots. <br/>The modification is further described in sections VII.2.1 and VII.2.2 below, but in short NHS England were required to (i) modify the Current Framework with the Absent Suppliers (as defined below) so as to extend the Current Framework for those Absent Products (as defined below) for a further period of (i) 3-months for IVIg products (Lots 1, 2, 5 and 6) (so to 30th September 2025) and (ii) 6-months for SCIg products (Lots 3 and 7) (so to 31st December 2025) and (ii) increase the estimated value of the Current Framework from PS1.2bn to PS1.6bn (an increase of 33%).",
"awardCriteria": {
"criteria": [
{
"name": "Security of Supply",
"type": "quality",
"description": "30%"
},
{
"name": "usability",
"type": "quality",
"description": "10%"
},
{
"type": "price",
"description": "60%"
}
]
},
"hasOptions": true,
"options": {
"description": "option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months"
},
"status": "cancelled",
"contractPeriod": {
"startDate": "2021-07-01T00:00:00+01:00",
"endDate": "2025-03-31T23:59:59+01:00"
}
},
{
"id": "2",
"title": "Lot 2: 10% Intravenous Immunoglobulin (10% IVIg)",
"description": "10% Intravenous Immunoglobulin (10% IVIg)",
"awardCriteria": {
"criteria": [
{
"name": "Security of Supply",
"type": "quality",
"description": "30%"
},
{
"name": "Usability",
"type": "quality",
"description": "10%"
},
{
"type": "price",
"description": "60%"
}
]
},
"hasOptions": true,
"options": {
"description": "option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months"
},
"status": "cancelled"
},
{
"id": "3",
"title": "Lot 3: Subcutaneous Immunoglobulin (SCIg)",
"description": "Subcutaneous Immunoglobulin (SCIg)",
"awardCriteria": {
"criteria": [
{
"name": "Usability",
"type": "quality",
"description": "10%"
},
{
"name": "Security of Supply",
"type": "quality",
"description": "30%"
},
{
"type": "price",
"description": "60%"
}
]
},
"hasOptions": true,
"options": {
"description": "option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months"
},
"status": "cancelled"
},
{
"id": "4",
"title": "Lot 4: Facilitated Subcutaneous Immunoglobulin (fSCIg)",
"description": "Facilitated Subcutaneous Immunoglobulin (fSCIg)",
"awardCriteria": {
"criteria": [
{
"name": "Security of Supply",
"type": "quality",
"description": "30%"
},
{
"name": "Usability",
"type": "quality",
"description": "10%"
},
{
"type": "price",
"description": "60%"
}
]
},
"hasOptions": true,
"options": {
"description": "option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months"
},
"status": "cancelled"
},
{
"id": "6",
"title": "Lot 6: 10% Intravenous Immunoglobulin (10% IVIg)",
"description": "10% Intravenous Immunoglobulin (10% IVIg)",
"awardCriteria": {
"criteria": [
{
"name": "Security of Supply",
"type": "quality",
"description": "30%"
},
{
"name": "Usability",
"type": "quality",
"description": "10%"
},
{
"type": "price",
"description": "60%"
}
]
},
"hasOptions": true,
"options": {
"description": "option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months"
},
"status": "cancelled"
},
{
"id": "5",
"title": "Lot 5: 5% Intravenous Immunoglobulin (5% IVIg)",
"description": "5: 5% Intravenous Immunoglobulin (5% IVIg)",
"awardCriteria": {
"criteria": [
{
"name": "Security of Supply",
"type": "quality",
"description": "30%"
},
{
"name": "Usability",
"type": "quality",
"description": "10%"
},
{
"type": "price",
"description": "60%"
}
]
},
"hasOptions": true,
"options": {
"description": "option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months"
},
"status": "cancelled"
},
{
"id": "7",
"title": "Lot 7: Subcutaneous Immunoglobulin (SCIg)",
"description": "Subcutaneous Immunoglobulin (SCIg)",
"awardCriteria": {
"criteria": [
{
"name": "Security of Supply",
"type": "quality",
"description": "30%"
},
{
"name": "Usability",
"type": "quality",
"description": "10%"
},
{
"type": "price",
"description": "60%"
}
]
},
"hasOptions": true,
"options": {
"description": "option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months"
},
"status": "cancelled"
},
{
"id": "9",
"title": "Lot 9: Anti-D Immunoglobulin (Anti-D)",
"description": "Anti-D Immunoglobulin (Anti-D)",
"awardCriteria": {
"criteria": [
{
"name": "Security of Supply",
"type": "quality",
"description": "30%"
},
{
"name": "Usability",
"type": "quality",
"description": "10%"
},
{
"type": "price",
"description": "60%"
}
]
},
"hasOptions": true,
"options": {
"description": "option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months"
},
"status": "cancelled"
},
{
"id": "8",
"title": "Lot 8: Facilitated Subcutaneous Immunoglobulin (fSCIg)",
"description": "Facilitated Subcutaneous Immunoglobulin (fSCIg)",
"awardCriteria": {
"criteria": [
{
"name": "Security of Supply",
"type": "quality",
"description": "30%"
},
{
"name": "Usability",
"type": "quality",
"description": "10%"
},
{
"type": "price",
"description": "60%"
}
]
},
"hasOptions": true,
"options": {
"description": "option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months"
},
"status": "cancelled"
}
],
"items": [
{
"id": "1-9",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33651520",
"description": "Immunoglobulins"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framwork intended for use by the NHS in England, Scotland Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of the above"
},
"relatedLot": "1-9"
},
{
"id": "1",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33651520",
"description": "Immunoglobulins"
}
],
"deliveryAddresses": [
{
"region": "UK"
},
{
"region": "UK"
},
{
"region": "UK"
},
{
"region": "UK"
},
{
"region": "UK"
},
{
"region": "UK"
},
{
"region": "UK"
},
{
"region": "UK"
},
{
"region": "UK"
},
{
"region": "UK"
},
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "Please refer to Document 04d Schedule 8 in the ITO for the list of purchasing points"
},
"relatedLot": "1"
},
{
"id": "2",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33651520",
"description": "Immunoglobulins"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "Please refer to Document 04d Schedule 8 in the ITO for the list of purchasing points"
},
"relatedLot": "2"
},
{
"id": "3",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33651520",
"description": "Immunoglobulins"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "Please refer to Document 04d Schedule 8 in the ITO for the list of purchasing points"
},
"relatedLot": "3"
},
{
"id": "4",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33651520",
"description": "Immunoglobulins"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "Please refer to Document 04d Schedule 8 in the ITO for the list of purchasing points"
},
"relatedLot": "4"
},
{
"id": "6",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33651520",
"description": "Immunoglobulins"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "Please refer to Document 04d Schedule 8 in the ITO for the list of purchasing points"
},
"relatedLot": "6"
},
{
"id": "5",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33651520",
"description": "Immunoglobulins"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "Please refer to Document 04d Schedule 8 in the ITO for the list of purchasing points"
},
"relatedLot": "5"
},
{
"id": "7",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33651520",
"description": "Immunoglobulins"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "Please refer to Document 04d Schedule 8 in the ITO for the list of purchasing points"
},
"relatedLot": "7"
},
{
"id": "9",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33651520",
"description": "Immunoglobulins"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "Please refer to Document 04d Schedule 8 in the ITO for the list of purchasing points"
},
"relatedLot": "9"
},
{
"id": "8",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33651520",
"description": "Immunoglobulins"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"relatedLot": "8"
}
],
"submissionMethod": [
"electronicSubmission",
"written"
],
"submissionMethodDetails": "http://health.atamis.co.uk",
"communication": {
"atypicalToolUrl": "http://health.atamis.co.uk"
},
"documents": [
{
"id": "economic",
"documentType": "economicSelectionCriteria"
},
{
"id": "technical",
"documentType": "technicalSelectionCriteria"
}
],
"procurementMethod": "open",
"procurementMethodDetails": "Open procedure",
"techniques": {
"hasFrameworkAgreement": true
},
"coveredBy": [
"GPA"
],
"tenderPeriod": {
"endDate": "2021-02-26T13:00:00Z"
},
"submissionTerms": {
"languages": [
"en"
],
"bidValidityPeriod": {
"endDate": "2021-05-27T23:59:59+01:00"
}
},
"awardPeriod": {
"startDate": "2021-02-26T13:00:00Z"
},
"bidOpening": {
"date": "2021-02-26T13:00:00Z",
"address": {
"streetAddress": "Runcorn"
},
"description": "Commercial Medicines Unit Employee"
},
"hasRecurrence": false,
"contractTerms": {
"hasElectronicOrdering": true,
"electronicInvoicingPolicy": "allowed",
"hasElectronicPayment": true
}
},
"parties": [
{
"id": "GB-FTS-2505",
"name": "The NHS Commissioning Board (operating under the name of NHS England)",
"identifier": {
"legalName": "The NHS Commissioning Board (operating under the name of NHS England)"
},
"address": {
"streetAddress": "2nd Floor, Rutland House",
"locality": "Runcorn",
"region": "UK",
"postalCode": "WA7 2ES",
"countryName": "United Kingdom"
},
"contactPoint": {
"name": "Philip Grieve",
"email": "philip.grieve@nhs.net",
"url": "http://health.atamis.co.uk"
},
"roles": [
"buyer",
"centralPurchasingBody"
],
"details": {
"url": "https://www.england.nhs.uk/",
"buyerProfile": "https://www.england.nhs.uk/",
"classifications": [
{
"scheme": "TED_CA_TYPE",
"id": "MINISTRY",
"description": "Ministry or any other national or federal authority, including their regional or local subdivisions"
},
{
"scheme": "COFOG",
"id": "07",
"description": "Health"
}
]
}
},
{
"id": "GB-FTS-497",
"name": "The High Court",
"identifier": {
"legalName": "The High Court"
},
"address": {
"streetAddress": "Strand",
"locality": "London",
"postalCode": "WC2A 2LL",
"countryName": "United Kingdom"
},
"roles": [
"reviewBody"
],
"details": {
"url": "https://www.gov.uk/courts-tribunals"
},
"contactPoint": {
"email": "generaloffice@administrativecourtoffice.justice.gov.uk"
}
},
{
"id": "GB-FTS-23168",
"name": "Octapharma Limited",
"identifier": {
"legalName": "Octapharma Limited"
},
"address": {
"locality": "Manchester",
"region": "UK",
"postalCode": "M2 1AB",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "large"
}
},
{
"id": "GB-FTS-23169",
"name": "Shire Pharmaceuticals Ltd",
"identifier": {
"legalName": "Shire Pharmaceuticals Ltd"
},
"address": {
"locality": "London",
"region": "UK",
"postalCode": "W2 6BD",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "large"
}
},
{
"id": "GB-FTS-23170",
"name": "Biotest UK Limited",
"identifier": {
"legalName": "Biotest UK Limited"
},
"address": {
"locality": "Longbridge",
"region": "UK",
"postalCode": "B31 2UQ",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "sme"
}
},
{
"id": "GB-FTS-23171",
"name": "Grifols UK Ltd.",
"identifier": {
"legalName": "Grifols UK Ltd."
},
"address": {
"locality": "Cambridge",
"region": "UK",
"postalCode": "CB4 0WZ",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "large"
}
},
{
"id": "GB-FTS-23172",
"name": "Bio Products Laboratory Ltd",
"identifier": {
"legalName": "Bio Products Laboratory Ltd"
},
"address": {
"locality": "Elstree",
"region": "UK",
"postalCode": "B31 2UQ",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "large"
}
},
{
"id": "GB-FTS-23173",
"name": "LFB",
"identifier": {
"legalName": "LFB"
},
"address": {
"locality": "London",
"region": "UK",
"postalCode": "N6 9BR",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "large"
}
},
{
"id": "GB-FTS-23174",
"name": "CSL Behring UK Ltd",
"identifier": {
"legalName": "CSL Behring UK Ltd"
},
"address": {
"locality": "Haywards Heath",
"region": "UK",
"postalCode": "RH16 1AH",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "large"
}
},
{
"id": "GB-FTS-130973",
"name": "NHS England",
"identifier": {
"legalName": "NHS England"
},
"address": {
"streetAddress": "Wellington House, 133-135 Waterloo Rd",
"locality": "London",
"region": "UKJ1",
"postalCode": "SE1 8UG",
"countryName": "United Kingdom"
},
"contactPoint": {
"name": "Mark Perkins",
"email": "mark.perkins@nhs.net"
},
"roles": [
"buyer"
],
"details": {
"url": "https://www.england.nhs.uk/",
"buyerProfile": "https://www.england.nhs.uk/"
}
},
{
"id": "GB-FTS-132779",
"name": "BIO PRODUCTS LABORATORY LIMITED",
"identifier": {
"legalName": "BIO PRODUCTS LABORATORY LIMITED",
"id": "07343036"
},
"address": {
"streetAddress": "C/O Bio Products Laboratory, Dagger Lane, Elstree, Hertfordshire, WD6 3BX",
"locality": "Elstree",
"region": "UK",
"postalCode": "WD6 3BX",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"url": "http://www.bpl.co.uk",
"scale": "large"
}
},
{
"id": "GB-FTS-1661",
"name": "The High Court",
"identifier": {
"legalName": "The High Court"
},
"address": {
"streetAddress": "The Strand",
"locality": "London",
"postalCode": "WC2A 2LL",
"countryName": "United Kingdom"
},
"roles": [
"reviewBody",
"mediationBody"
],
"details": {
"url": "https://www.judiciary.uk/courts-and-tribunals/high-court/"
}
}
],
"buyer": {
"id": "GB-FTS-130973",
"name": "NHS England"
},
"language": "en",
"awards": [
{
"id": "017380-2021-1",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23168",
"name": "Octapharma Limited"
}
]
},
{
"id": "017380-2021-2",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23169",
"name": "Shire Pharmaceuticals Ltd"
}
]
},
{
"id": "017380-2021-3",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23170",
"name": "Biotest UK Limited"
}
]
},
{
"id": "017380-2021-4",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23171",
"name": "Grifols UK Ltd."
}
]
},
{
"id": "017380-2021-5",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23172",
"name": "Bio Products Laboratory Ltd"
}
]
},
{
"id": "017380-2021-6",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23168",
"name": "Octapharma Limited"
}
]
},
{
"id": "017380-2021-7",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23169",
"name": "Shire Pharmaceuticals Ltd"
}
]
},
{
"id": "017380-2021-8",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23170",
"name": "Biotest UK Limited"
}
]
},
{
"id": "017380-2021-9",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23173",
"name": "LFB"
}
]
},
{
"id": "017380-2021-10",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23171",
"name": "Grifols UK Ltd."
}
]
},
{
"id": "017380-2021-11",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23172",
"name": "Bio Products Laboratory Ltd"
}
]
},
{
"id": "017380-2021-12",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23174",
"name": "CSL Behring UK Ltd"
}
]
},
{
"id": "017380-2021-13",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23168",
"name": "Octapharma Limited"
}
]
},
{
"id": "017380-2021-14",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23169",
"name": "Shire Pharmaceuticals Ltd"
}
]
},
{
"id": "017380-2021-15",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23172",
"name": "Bio Products Laboratory Ltd"
}
]
},
{
"id": "017380-2021-16",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23174",
"name": "CSL Behring UK Ltd"
}
]
},
{
"id": "017380-2021-17",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23169",
"name": "Shire Pharmaceuticals Ltd"
}
]
},
{
"id": "017380-2021-18",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23168",
"name": "Octapharma Limited"
}
]
},
{
"id": "017380-2021-19",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23169",
"name": "Shire Pharmaceuticals Ltd"
}
]
},
{
"id": "017380-2021-20",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23170",
"name": "Biotest UK Limited"
}
]
},
{
"id": "017380-2021-21",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23173",
"name": "LFB"
}
]
},
{
"id": "017380-2021-22",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23171",
"name": "Grifols UK Ltd."
}
]
},
{
"id": "017380-2021-23",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23172",
"name": "Bio Products Laboratory Ltd"
}
]
},
{
"id": "017380-2021-24",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23174",
"name": "CSL Behring UK Ltd"
}
]
},
{
"id": "017380-2021-25",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23168",
"name": "Octapharma Limited"
}
]
},
{
"id": "017380-2021-26",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23169",
"name": "Shire Pharmaceuticals Ltd"
}
]
},
{
"id": "017380-2021-27",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23170",
"name": "Biotest UK Limited"
}
]
},
{
"id": "017380-2021-28",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23171",
"name": "Grifols UK Ltd."
}
]
},
{
"id": "017380-2021-29",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23172",
"name": "Bio Products Laboratory Ltd"
}
]
},
{
"id": "017380-2021-30",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23168",
"name": "Octapharma Limited"
}
]
},
{
"id": "017380-2021-31",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23169",
"name": "Shire Pharmaceuticals Ltd"
}
]
},
{
"id": "017380-2021-32",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23172",
"name": "Bio Products Laboratory Ltd"
}
]
},
{
"id": "017380-2021-33",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23174",
"name": "CSL Behring UK Ltd"
}
]
},
{
"id": "017380-2021-34",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23172",
"name": "Bio Products Laboratory Ltd"
}
]
},
{
"id": "017380-2021-35",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23174",
"name": "CSL Behring UK Ltd"
}
]
},
{
"id": "017380-2021-36",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-23169",
"name": "Shire Pharmaceuticals Ltd"
}
]
},
{
"id": "040318-2024-2021/S 000-017380-1",
"relatedLots": [
"1"
],
"title": "NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-132779",
"name": "BIO PRODUCTS LABORATORY LIMITED"
}
]
},
{
"id": "040395-2024-2021/S 000-017380-1",
"relatedLots": [
"1"
],
"title": "NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-132779",
"name": "BIO PRODUCTS LABORATORY LIMITED"
}
]
},
{
"id": "040398-2024-2021/S 000-017380-1",
"relatedLots": [
"1"
],
"title": "NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-132779",
"name": "BIO PRODUCTS LABORATORY LIMITED"
}
]
},
{
"id": "040399-2024-2021/S 000-017380-1",
"relatedLots": [
"1"
],
"title": "NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-132779",
"name": "BIO PRODUCTS LABORATORY LIMITED"
}
]
},
{
"id": "040400-2024-2021/S 000-017380-1",
"relatedLots": [
"1"
],
"title": "NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-132779",
"name": "BIO PRODUCTS LABORATORY LIMITED"
}
]
},
{
"id": "040401-2024-2021/S 000-017380-1",
"relatedLots": [
"1"
],
"title": "NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-132779",
"name": "BIO PRODUCTS LABORATORY LIMITED"
}
]
},
{
"id": "040403-2024-2021/S 000-017380-1",
"relatedLots": [
"1"
],
"title": "NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-132779",
"name": "BIO PRODUCTS LABORATORY LIMITED"
}
]
},
{
"id": "040404-2024-2021/S 000-017380-1",
"relatedLots": [
"1"
],
"title": "NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-132779",
"name": "BIO PRODUCTS LABORATORY LIMITED"
}
]
},
{
"id": "040405-2024-2021/S 000-017380-1",
"relatedLots": [
"1"
],
"title": "NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-132779",
"name": "BIO PRODUCTS LABORATORY LIMITED"
}
]
},
{
"id": "040406-2024-2021/S 000-017380-1",
"relatedLots": [
"1"
],
"title": "NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-132779",
"name": "BIO PRODUCTS LABORATORY LIMITED"
}
]
}
],
"contracts": [
{
"id": "017380-2021-1",
"awardID": "017380-2021-1",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-2",
"awardID": "017380-2021-2",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-3",
"awardID": "017380-2021-3",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-4",
"awardID": "017380-2021-4",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-5",
"awardID": "017380-2021-5",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-6",
"awardID": "017380-2021-6",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-7",
"awardID": "017380-2021-7",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-8",
"awardID": "017380-2021-8",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-9",
"awardID": "017380-2021-9",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-10",
"awardID": "017380-2021-10",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-11",
"awardID": "017380-2021-11",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-12",
"awardID": "017380-2021-12",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-13",
"awardID": "017380-2021-13",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-14",
"awardID": "017380-2021-14",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-15",
"awardID": "017380-2021-15",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-16",
"awardID": "017380-2021-16",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-17",
"awardID": "017380-2021-17",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-18",
"awardID": "017380-2021-18",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-19",
"awardID": "017380-2021-19",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-20",
"awardID": "017380-2021-20",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-21",
"awardID": "017380-2021-21",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-22",
"awardID": "017380-2021-22",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-23",
"awardID": "017380-2021-23",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-24",
"awardID": "017380-2021-24",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-25",
"awardID": "017380-2021-25",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-26",
"awardID": "017380-2021-26",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-27",
"awardID": "017380-2021-27",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-28",
"awardID": "017380-2021-28",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-29",
"awardID": "017380-2021-29",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-30",
"awardID": "017380-2021-30",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-31",
"awardID": "017380-2021-31",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-32",
"awardID": "017380-2021-32",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-33",
"awardID": "017380-2021-33",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-34",
"awardID": "017380-2021-34",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-35",
"awardID": "017380-2021-35",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "017380-2021-36",
"awardID": "017380-2021-36",
"title": "Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00"
},
{
"id": "040318-2024-2021/S 000-017380-1",
"awardID": "040318-2024-2021/S 000-017380-1",
"title": "NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1600000000,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00",
"period": {
"startDate": "2021-07-01T00:00:00+01:00",
"endDate": "2025-03-31T23:59:59+01:00"
},
"items": [
{
"id": "1",
"classification": {
"scheme": "CPV",
"id": "33651520",
"description": "Immunoglobulins"
},
"deliveryAddresses": [
{
"region": "UK"
}
],
"relatedLot": "1"
}
],
"amendments": [
{
"id": "1",
"description": "Please refer to section VI.3.0.1 Additional information",
"rationale": "Need for additional works, services or supplies by the original contractor/concessionaire: Please refer to section VI.3.0.1 Additional information"
}
]
},
{
"id": "040395-2024-2021/S 000-017380-1",
"awardID": "040395-2024-2021/S 000-017380-1",
"title": "NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1600000000,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00",
"period": {
"startDate": "2021-07-01T00:00:00+01:00",
"endDate": "2025-03-31T23:59:59+01:00"
},
"items": [
{
"id": "1",
"classification": {
"scheme": "CPV",
"id": "33651520",
"description": "Immunoglobulins"
},
"deliveryAddresses": [
{
"region": "UK"
}
],
"relatedLot": "1"
}
],
"amendments": [
{
"id": "2",
"description": "Please refer to section VI.3.0.1 Additional information",
"rationale": "Need for additional works, services or supplies by the original contractor/concessionaire: Please refer to section VI.3.0.1 Additional information"
}
]
},
{
"id": "040398-2024-2021/S 000-017380-1",
"awardID": "040398-2024-2021/S 000-017380-1",
"title": "NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1600000000,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00",
"period": {
"startDate": "2021-07-01T00:00:00+01:00",
"endDate": "2025-03-31T23:59:59+01:00"
},
"items": [
{
"id": "1",
"classification": {
"scheme": "CPV",
"id": "33651520",
"description": "Immunoglobulins"
},
"deliveryAddresses": [
{
"region": "UK"
}
],
"relatedLot": "1"
}
],
"amendments": [
{
"id": "3",
"description": "Please refer to section VI.3.0.1 Additional information",
"rationale": "Need for additional works, services or supplies by the original contractor/concessionaire: Please refer to section VI.3.0.1 Additional information"
}
]
},
{
"id": "040399-2024-2021/S 000-017380-1",
"awardID": "040399-2024-2021/S 000-017380-1",
"title": "NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1600000000,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00",
"period": {
"startDate": "2021-07-01T00:00:00+01:00",
"endDate": "2025-03-31T23:59:59+01:00"
},
"items": [
{
"id": "1",
"classification": {
"scheme": "CPV",
"id": "33651520",
"description": "Immunoglobulins"
},
"deliveryAddresses": [
{
"region": "UK"
}
],
"relatedLot": "1"
}
],
"amendments": [
{
"id": "4",
"description": "Please refer to section VI.3.0.1 Additional information",
"rationale": "Need for additional works, services or supplies by the original contractor/concessionaire: Please refer to section VI.3.0.1 Additional information"
}
]
},
{
"id": "040400-2024-2021/S 000-017380-1",
"awardID": "040400-2024-2021/S 000-017380-1",
"title": "NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1600000000,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00",
"period": {
"startDate": "2021-07-01T00:00:00+01:00",
"endDate": "2025-03-31T23:59:59+01:00"
},
"items": [
{
"id": "1",
"classification": {
"scheme": "CPV",
"id": "33651520",
"description": "Immunoglobulins"
},
"deliveryAddresses": [
{
"region": "UK"
}
],
"relatedLot": "1"
}
],
"amendments": [
{
"id": "5",
"description": "Please refer to section VI.3.0.1 Additional information",
"rationale": "Need for additional works, services or supplies by the original contractor/concessionaire: Please refer to section VI.3.0.1 Additional information"
}
]
},
{
"id": "040401-2024-2021/S 000-017380-1",
"awardID": "040401-2024-2021/S 000-017380-1",
"title": "NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1600000000,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00",
"period": {
"startDate": "2021-07-01T00:00:00+01:00",
"endDate": "2025-03-31T23:59:59+01:00"
},
"items": [
{
"id": "1",
"classification": {
"scheme": "CPV",
"id": "33651520",
"description": "Immunoglobulins"
},
"deliveryAddresses": [
{
"region": "UK"
}
],
"relatedLot": "1"
}
],
"amendments": [
{
"id": "6",
"description": "Please refer to section VI.3.0.1 Additional information",
"rationale": "Need for additional works, services or supplies by the original contractor/concessionaire: Please refer to section VI.3.0.1 Additional information"
}
]
},
{
"id": "040403-2024-2021/S 000-017380-1",
"awardID": "040403-2024-2021/S 000-017380-1",
"title": "NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1600000000,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00",
"period": {
"startDate": "2021-07-01T00:00:00+01:00",
"endDate": "2025-03-31T23:59:59+01:00"
},
"items": [
{
"id": "1",
"classification": {
"scheme": "CPV",
"id": "33651520",
"description": "Immunoglobulins"
},
"deliveryAddresses": [
{
"region": "UK"
}
],
"relatedLot": "1"
}
],
"amendments": [
{
"id": "7",
"description": "Please refer to section VI.3.0.1 Additional information",
"rationale": "Need for additional works, services or supplies by the original contractor/concessionaire: Please refer to section VI.3.0.1 Additional information"
}
]
},
{
"id": "040404-2024-2021/S 000-017380-1",
"awardID": "040404-2024-2021/S 000-017380-1",
"title": "NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1600000000,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00",
"period": {
"startDate": "2021-07-01T00:00:00+01:00",
"endDate": "2025-03-31T23:59:59+01:00"
},
"items": [
{
"id": "1",
"classification": {
"scheme": "CPV",
"id": "33651520",
"description": "Immunoglobulins"
},
"deliveryAddresses": [
{
"region": "UK"
}
],
"relatedLot": "1"
}
],
"amendments": [
{
"id": "8",
"description": "Please refer to section VI.3.0.1 Additional information",
"rationale": "Need for additional works, services or supplies by the original contractor/concessionaire: Please refer to section VI.3.0.1 Additional information"
}
]
},
{
"id": "040405-2024-2021/S 000-017380-1",
"awardID": "040405-2024-2021/S 000-017380-1",
"title": "NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1600000000,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00",
"period": {
"startDate": "2021-07-01T00:00:00+01:00",
"endDate": "2025-03-31T23:59:59+01:00"
},
"items": [
{
"id": "1",
"classification": {
"scheme": "CPV",
"id": "33651520",
"description": "Immunoglobulins"
},
"deliveryAddresses": [
{
"region": "UK"
}
],
"relatedLot": "1"
}
],
"amendments": [
{
"id": "9",
"description": "Please refer to section VI.3.0.1 Additional information",
"rationale": "Need for additional works, services or supplies by the original contractor/concessionaire: Please refer to section VI.3.0.1 Additional information"
}
]
},
{
"id": "040406-2024-2021/S 000-017380-1",
"awardID": "040406-2024-2021/S 000-017380-1",
"title": "NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin",
"status": "active",
"value": {
"amount": 1600000000,
"currency": "GBP"
},
"dateSigned": "2021-06-23T00:00:00+01:00",
"period": {
"startDate": "2021-07-01T00:00:00+01:00",
"endDate": "2025-03-31T23:59:59+01:00"
},
"items": [
{
"id": "1",
"classification": {
"scheme": "CPV",
"id": "33651520",
"description": "Immunoglobulins"
},
"deliveryAddresses": [
{
"region": "UK"
}
],
"relatedLot": "1"
}
],
"amendments": [
{
"id": "10",
"description": "Please refer to section VI.3.0.1 Additional information",
"rationale": "Need for additional works, services or supplies by the original contractor/concessionaire: Please refer to section VI.3.0.1 Additional information"
}
]
}
],
"bids": {
"statistics": [
{
"id": "1",
"measure": "bids",
"value": 7
},
{
"id": "6",
"measure": "bids",
"value": 7
},
{
"id": "11",
"measure": "bids",
"value": 7
},
{
"id": "16",
"measure": "bids",
"value": 7
},
{
"id": "21",
"measure": "bids",
"value": 7
},
{
"id": "26",
"measure": "bids",
"value": 7
},
{
"id": "31",
"measure": "bids",
"value": 7
},
{
"id": "36",
"measure": "bids",
"value": 7
},
{
"id": "41",
"measure": "bids",
"value": 7
},
{
"id": "46",
"measure": "bids",
"value": 7
},
{
"id": "51",
"measure": "bids",
"value": 7
},
{
"id": "56",
"measure": "bids",
"value": 7
},
{
"id": "61",
"measure": "bids",
"value": 7
},
{
"id": "66",
"measure": "bids",
"value": 7
},
{
"id": "71",
"measure": "bids",
"value": 7
},
{
"id": "76",
"measure": "bids",
"value": 7
},
{
"id": "81",
"measure": "bids",
"value": 7
},
{
"id": "86",
"measure": "bids",
"value": 7
},
{
"id": "91",
"measure": "bids",
"value": 7
},
{
"id": "96",
"measure": "bids",
"value": 7
},
{
"id": "101",
"measure": "bids",
"value": 7
},
{
"id": "106",
"measure": "bids",
"value": 7
},
{
"id": "111",
"measure": "bids",
"value": 7
},
{
"id": "116",
"measure": "bids",
"value": 7
},
{
"id": "121",
"measure": "bids",
"value": 7
},
{
"id": "126",
"measure": "bids",
"value": 7
},
{
"id": "131",
"measure": "bids",
"value": 7
},
{
"id": "136",
"measure": "bids",
"value": 7
},
{
"id": "141",
"measure": "bids",
"value": 7
},
{
"id": "146",
"measure": "bids",
"value": 7
},
{
"id": "151",
"measure": "bids",
"value": 7
},
{
"id": "156",
"measure": "bids",
"value": 7
},
{
"id": "161",
"measure": "bids",
"value": 7
},
{
"id": "166",
"measure": "bids",
"value": 7
},
{
"id": "171",
"measure": "bids",
"value": 7
},
{
"id": "176",
"measure": "bids",
"value": 7
},
{
"id": "2",
"measure": "smeBids",
"value": 1
},
{
"id": "7",
"measure": "smeBids",
"value": 1
},
{
"id": "12",
"measure": "smeBids",
"value": 1
},
{
"id": "17",
"measure": "smeBids",
"value": 1
},
{
"id": "22",
"measure": "smeBids",
"value": 1
},
{
"id": "27",
"measure": "smeBids",
"value": 1
},
{
"id": "32",
"measure": "smeBids",
"value": 1
},
{
"id": "37",
"measure": "smeBids",
"value": 1
},
{
"id": "42",
"measure": "smeBids",
"value": 1
},
{
"id": "47",
"measure": "smeBids",
"value": 1
},
{
"id": "52",
"measure": "smeBids",
"value": 1
},
{
"id": "57",
"measure": "smeBids",
"value": 1
},
{
"id": "62",
"measure": "smeBids",
"value": 1
},
{
"id": "67",
"measure": "smeBids",
"value": 1
},
{
"id": "72",
"measure": "smeBids",
"value": 1
},
{
"id": "77",
"measure": "smeBids",
"value": 1
},
{
"id": "82",
"measure": "smeBids",
"value": 1
},
{
"id": "87",
"measure": "smeBids",
"value": 1
},
{
"id": "92",
"measure": "smeBids",
"value": 1
},
{
"id": "97",
"measure": "smeBids",
"value": 1
},
{
"id": "102",
"measure": "smeBids",
"value": 1
},
{
"id": "107",
"measure": "smeBids",
"value": 1
},
{
"id": "112",
"measure": "smeBids",
"value": 1
},
{
"id": "117",
"measure": "smeBids",
"value": 1
},
{
"id": "122",
"measure": "smeBids",
"value": 1
},
{
"id": "127",
"measure": "smeBids",
"value": 1
},
{
"id": "132",
"measure": "smeBids",
"value": 1
},
{
"id": "137",
"measure": "smeBids",
"value": 1
},
{
"id": "142",
"measure": "smeBids",
"value": 1
},
{
"id": "147",
"measure": "smeBids",
"value": 1
},
{
"id": "152",
"measure": "smeBids",
"value": 1
},
{
"id": "157",
"measure": "smeBids",
"value": 1
},
{
"id": "162",
"measure": "smeBids",
"value": 1
},
{
"id": "167",
"measure": "smeBids",
"value": 1
},
{
"id": "172",
"measure": "smeBids",
"value": 1
},
{
"id": "177",
"measure": "smeBids",
"value": 1
},
{
"id": "3",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "8",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "13",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "18",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "23",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "28",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "33",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "38",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "43",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "48",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "53",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "58",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "63",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "68",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "73",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "78",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "83",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "88",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "93",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "98",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "103",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "108",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "113",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "118",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "123",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "128",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "133",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "138",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "143",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "148",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "153",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "158",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "163",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "168",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "173",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "178",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "4",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "9",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "14",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "19",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "24",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "29",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "34",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "39",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "44",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "49",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "54",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "59",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "64",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "69",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "74",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "79",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "84",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "89",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "94",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "99",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "104",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "109",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "114",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "119",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "124",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "129",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "134",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "139",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "144",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "149",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "154",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "159",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "164",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "169",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "174",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "179",
"measure": "foreignBidsFromNonEU",
"value": 0
},
{
"id": "5",
"measure": "electronicBids",
"value": 7
},
{
"id": "10",
"measure": "electronicBids",
"value": 7
},
{
"id": "15",
"measure": "electronicBids",
"value": 7
},
{
"id": "20",
"measure": "electronicBids",
"value": 7
},
{
"id": "25",
"measure": "electronicBids",
"value": 7
},
{
"id": "30",
"measure": "electronicBids",
"value": 7
},
{
"id": "35",
"measure": "electronicBids",
"value": 7
},
{
"id": "40",
"measure": "electronicBids",
"value": 7
},
{
"id": "45",
"measure": "electronicBids",
"value": 7
},
{
"id": "50",
"measure": "electronicBids",
"value": 7
},
{
"id": "55",
"measure": "electronicBids",
"value": 7
},
{
"id": "60",
"measure": "electronicBids",
"value": 7
},
{
"id": "65",
"measure": "electronicBids",
"value": 7
},
{
"id": "70",
"measure": "electronicBids",
"value": 7
},
{
"id": "75",
"measure": "electronicBids",
"value": 7
},
{
"id": "80",
"measure": "electronicBids",
"value": 7
},
{
"id": "85",
"measure": "electronicBids",
"value": 7
},
{
"id": "90",
"measure": "electronicBids",
"value": 7
},
{
"id": "95",
"measure": "electronicBids",
"value": 7
},
{
"id": "100",
"measure": "electronicBids",
"value": 7
},
{
"id": "105",
"measure": "electronicBids",
"value": 7
},
{
"id": "110",
"measure": "electronicBids",
"value": 7
},
{
"id": "115",
"measure": "electronicBids",
"value": 7
},
{
"id": "120",
"measure": "electronicBids",
"value": 7
},
{
"id": "125",
"measure": "electronicBids",
"value": 7
},
{
"id": "130",
"measure": "electronicBids",
"value": 7
},
{
"id": "135",
"measure": "electronicBids",
"value": 7
},
{
"id": "140",
"measure": "electronicBids",
"value": 7
},
{
"id": "145",
"measure": "electronicBids",
"value": 7
},
{
"id": "150",
"measure": "electronicBids",
"value": 7
},
{
"id": "155",
"measure": "electronicBids",
"value": 7
},
{
"id": "160",
"measure": "electronicBids",
"value": 7
},
{
"id": "165",
"measure": "electronicBids",
"value": 7
},
{
"id": "170",
"measure": "electronicBids",
"value": 7
},
{
"id": "175",
"measure": "electronicBids",
"value": 7
},
{
"id": "180",
"measure": "electronicBids",
"value": 7
}
]
}
}